Healthcare

Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.

HB 218 revises the practice of optometry by expanding the scope of services licensed optometrists can provide. It permits optometrists to perform certain in-office surgical procedures and laser surgical procedures, specifically limited to the anterior segment of the eye and adnexa. However, the bill explicitly excludes penetrating intraocular surgery, intravitreal injection, and refractive surgery. To perform laser surgical procedures, optometrists must be certified by the board after completing required didactic and clinical training. This act takes effect on July 1, 2025.

HB 253 mandates that the Department of Public Health and Human Services (DPHHS) disclose specific health information daily during a declared public health emergency. This bill requires the DPHHS to publish on its website the total number of individuals hospitalized and those who have died due to the emergency, while adhering to confidentiality laws. For these categories, the department must provide breakdowns by age group, gender, length of hospitalization, date of death, and any contributing underlying conditions or personal characteristics. The aim is to provide the public with detailed, aggregated data about the health impacts of an emergency.

HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.